Research ArticleArticle
Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey
Anne Boel, Victoria Navarro-Compán, Annelies Boonen, Philip Mease, Uta Kiltz, Maxime Dougados, Robert Landewé and Désirée van der Heijde
The Journal of Rheumatology August 2021, jrheum.210206; DOI: https://doi.org/10.3899/jrheum.210206
Anne Boel
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Victoria Navarro-Compán
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Annelies Boonen
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Philip Mease
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Uta Kiltz
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Maxime Dougados
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Robert Landewé
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
Désirée van der Heijde
The Assessment of SpondyloArthritis international Society (ASAS) funded AB and VNC to work on the project to update the core outcome set. A. Boel, MSc, D. van der Heijde, MD, PhD, Rheumatology Department, Leiden University Medical Centre, Leiden, the Netherlands; V. Navarro-Compán, MD, PhD, Rheumatology Department, University Hospital La Paz, IdiPaz, Madrid, Spain; A. Boonen, MD, PhD, Prof, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; P.J. Mease, MD, PhD, Prof, Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA; U. Kiltz, MD, PhD, Rheumatology, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany; M. Dougados, MD, PhD, Prof, Rheumatology Department, Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France; R. Landewé, MD, PhD, Prof, Rheumatology Department, Zuyderland Medical Center Heerlen, Heerlen, and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Boel, Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, the Netherlands. Email: a.h.e.m.boel@lumc.nl. Accepted for publication July 14, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey
Anne Boel, Victoria Navarro-Compán, Annelies Boonen, Philip Mease, Uta Kiltz, Maxime Dougados, Robert Landewé, Désirée van der Heijde
The Journal of Rheumatology Aug 2021, jrheum.210206; DOI: 10.3899/jrheum.210206
Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey
Anne Boel, Victoria Navarro-Compán, Annelies Boonen, Philip Mease, Uta Kiltz, Maxime Dougados, Robert Landewé, Désirée van der Heijde
The Journal of Rheumatology Aug 2021, jrheum.210206; DOI: 10.3899/jrheum.210206